Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets

2026-09-28
MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

2026-09-28
MILAN, September 28, 2026--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk.

2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds

2026-09-25
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow

2026-09-25
DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...

Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?

2026-09-24
DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...

DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer

2026-09-23
DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...

Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring

2026-09-22
Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.

2 Nasdaq 100 Stocks for Long-Term Investors and 1 We Turn Down

2026-09-21
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.

Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key Players

2026-09-21
Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- "Wearable Biosensors Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of ch

Truist Securities Maintains Buy on DexCom, Raises Price Target to $102

2026-09-18
Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $93 to $102.